Výsledky vyhledávání - "Abatacept/therapeutic use"

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

Publikováno v: Annals of the Rheumatic Diseases, 81(10). BMJ PUBLISHING GROUP
Lauper, K, Hyrich, K L, Kearsley-Fleet, L & et al. 2022, ' Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31,846 patients with rheumatoid arthritis in 19 registers from the “JAK-pot” collaboration ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2022-222586
Lauper, K, Ludici, M, Mongin, D, Bergstra, S A, Choquette, D, Codreanu, C, Cordtz, R, De Cock, D, Dreyer, L, Elkayam, O, Hauge, E-M, Huschek, D, Hyrich, K L, Iannone, F, Inanc, N, Kearsley-Fleet, L, Kristianslund, E K, Kvien, T K, Leeb, B F, Lukina, G, Nordström, D C, Pavelka, K, Pombo-Suarez, M, Rotar, Z, Santos, M J, Strangfeld, A, Verschueren, P, Courvoisier, D S & Finckh, A 2022, ' Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration ', Annals of the Rheumatic Diseases, vol. 81, no. 10, 222586, pp. 1358-1366 . https://doi.org/10.1136/annrheumdis-2022-222586
Lauper, K, Iudici, M, Mongin, D, Bergstra, S A, Choquette, D, Codreanu, C, Cordtz, R, De Cock, D, Dreyer, L, Elkayam, O, Hauge, E M, Huschek, D, Hyrich, K L, Iannone, F, Inanc, N, Kearsley-Fleet, L, Kristianslund, E K, Kvien, T K, Leeb, B F, Lukina, G, Nordström, D C, Pavelka, K, Pombo-Suarez, M, Rotar, Z, Santos, M J, Strangfeld, A, Verschueren, P, Courvoisier, D S & Finckh, A 2022, ' Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration ', Annals of the Rheumatic Diseases, vol. 81, no. 10, pp. 1358-1366 . https://doi.org/10.1136/annrheumdis-2022-222586

BackgroundJAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05814942d68a76c3ecb33d7f6c01ede0
http://hdl.handle.net/10138/349608

Zobrazit plný text záznamu

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis

Autor: Harris A. Ahmad, Philip G. Conaghan, Patrick Durez, Subhashis Banerjee, Paul Emery, Joshua F. Baker, Mikkel Østergaard, J Ye

Publikováno v: Ahmad, H A, Baker, J F, Østergaard, M, Emery, P, Durez, P, Ye, J, Banerjee, S & Conaghan, P G 2020, ' Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis ', Arthritis Care and Research, vol. 72, no. 7, pp. 959-964 . https://doi.org/10.1002/acr.24072
Arthritis Care & Research

OBJECTIVE: High magnetic resonance imaging (MRI)-detected inflammation is associated with greater progression and poorer outcomes in rheumatoid arthritis (RA). This analysis aimed to determine if baseline MRI inflammation was related to clinical resp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb8f2f1a7e638b147269511e8e6a96c
https://curis.ku.dk/portal/da/publications/baseline-objective-inflammation-by-magnetic-resonance-imaging-as-a-predictor-of-therapeutic-benefit-in-early-rheumatoid-arthritis-with-poor-prognosis(80613ff7-ef49-4a5a-a3ad-8713b42b562c).html

Zobrazit plný text záznamu

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

Autor: Finckh, Axel, Tellenbach, C, Herzog, L, Scherer, A, Moeller, B, Ciurea, A, von Muehlenen, I, Gabay, Cem, Kyburz, D, Brulhart, Laure Sophie, Müller, R, Hasler, P, Zufferey, P, physicians and patients of the SCQM (Swiss Clinical Quality Management in Rheumatic Diseases)

Publikováno v: RMD Open, Vol. 6, No 1 (2020) P. e001174
RMD Open
RMD Open, Vol 6, Iss 1 (2020)

BackgroundMultiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c113cafe8cadf519c45d41d35142d2cd
https://hdl.handle.net/11475/25911

Zobrazit plný text záznamu

Allergologie-immunologie - Prise en charge de l'artérite gigantocellulaire en 2019

Autor: Allali, Danièle, Blondon, Marc, Roux-Lombard, Pascale, Spoerl, David

Publikováno v: Revue médicale suisse, Vol. 16, No 676-677 (2020) pp. 12-15

L'artérite à cellules géantes est une vasculite des gros vaisseaux fréquentes après 50 ans, nécessitant un traitement par corticostéroïdes dès le diagnostic pour diminuer les complications ischémiques. En raison des effets secondaires du tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1400::64ebedd30a56509b5f2e93fab7ef53f2
https://archive-ouverte.unige.ch/unige:145567

Zobrazit plný text záznamu

Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion?:An analysis of the AMPLE and ATTEST trials

Autor: Buch, Maya H, Johnsen, Alyssa, Schiff, Michael

Publikováno v: Buch, M H, Johnsen, A & Schiff, M 2019, ' Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials ', Clinical and Experimental Rheumatology, vol. 37, no. 1, pp. 127-132 . < https://www.clinexprheumatol.org/abstract.asp?a=12451 >

OBJECTIVES: To explore antinuclear autoantibody (ANA) and anti-double-stranded DNA (anti-dsDNA) autoantibody development during abatacept and tumour necrosis factor inhibitor (TNFi) treatment, and effects of switching from TNFi to abatacept in ANA/an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::8b7292e86f69a02519a91b279bc562d0
https://research.manchester.ac.uk/en/publications/a0ad6775-0cf7-478b-9232-39ae1098dce0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání